Martine Extermann

TL;DR: The treatment of metastatic breast cancer has evolved significantly with the introduction of aromatase inhibitors, new chemotherapeutic agents, and targeted biologic agents and is as effective as single agents compared to older and more toxic drug combinations.

TL;DR: In the setting of an experienced geriatric oncology team, patients with cognitive impairment appear more likely to receive standard oncologic therapies, and they are at high risk of concomitant depression.

TL;DR: A review of the published literature on a comprehensive geriatric assessment and comorbidity measurements in patients with hematologic malignancies and their correlation with outcomes identified the Charlson score and the Cumulative Illness Rating Scale-Geriatric as the most frequently used comorebidity instruments in the general setting, and the Hematopoietic Cell Transplantation-Comorbidities Index in the transplant setting.

TL;DR: Nearly one-fifth of older breast cancer survivors had high psychoneurological symptoms at diagnosis, which predicted clinically meaningful decrements in perceived cognition and function in the first 24 months after diagnosis.

TL;DR: This study examined whether sleep disturbance was associated with worse neurocognitive outcomes in breast cancer survivors and whether sleep effects on cognition varied by genotype.